Aislinn Antrim is a journalist for Pharmacy Times, writing for both AJMC - The American Journal of Managed Care and Pharmacy Times. Her articles focus on the latest developments in cancer treatments, specifically in breast cancer, as well as advancements in immunotherapy and the impact of obesity on cancer. Aislinn aims to provide valuable insights and information to healthcare professionals and patients in the field of oncology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Aislinn focuses on health, healthcare & pharmaceuticals, and scientific topics with an emphasis on breast cancer treatment and immunotherapy. Her articles often cite data to support the insights provided. When reaching out to her, ensure that you have access to reliable data and can provide evidence-based perspectives.
Given Aislinn's focus on clinical trials and developments in breast cancer treatment, she would be interested in pitches related to cutting-edge research findings or innovations in these areas. If your pitch is related to any of the specific topics she covers (such as HIV care or vaccines), make sure it includes substantial data-driven insights.
While there is no specified geographic focus for Aislinn’s coverage, her interest lies primarily in evidence-based research and advancements within the healthcare industry without a clear regional limitation.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Aislinn Antrim
Tirbanibulin is a microtubule inhibitor ointment and is now approved in a 350 mg package size as a 5-day topical field treatment for actinic keratosis of the face or scalp. The new approval increases the previous dosing for surface area treatment from 25 cm
By: Aislinn Antrim
The Supreme Court has rejected a lawsuit challenging the FDA's regulations of mifepristone, a common abortion pill. With the new ruling, announced Thursday, the pills will continue to be able to be mailed to patients without an in-person visit with a physician.
By: Aislinn Antrim
The autoinjector will provide another option for adults in addition to the prefilled syringe that is currently available.
By: Aislinn Antrim
Repotrectinib has also shown significant efficacy in ROS1 fusion-positive non¬–small cell lung cancer (NSCLC), which was also studied in the TRIDENT-1 trial.
By: Aislinn Antrim
Hyperhidrosis affects an estimated 10 million individuals in the US and is characterized by abnormally increased sweating, beyond what is necessary to regulate body temperature. According to a news release, the disproportionate sweat production has profound impacts on quality of life, including work productivity, daily activities, emotional well-being, and personal relationships. It is the third largest dermatology condition after acne and atopic dermatitis.
Pharmacists Can Help Patients Select Probiotic Products and Advise Them on When to Seek Further Care.
By: Aislinn Antrim
Although respiratory syncytial virus (RSV) can cause mild coldlike symptoms, some older adults may develop more severe lung infections, pneumonia, and long-lasting conditions.
By: Aislinn Antrim
New payment frameworks are emerging, but pharmacists need to be central to the ongoing food as medicine movement.
ALZ-801 has now progressed to the phase 3 APOLLOE4 study, designed to evaluate efficacy, safety, and biomarker and imaging effects.
By: Aislinn Antrim
FCS is a severe, rare genetic disease in which patients have extremely high triglyceride levels, typically above 880 mg/dL. Such elevations can lead to serious symptoms including acute and potentially fatal pancreatitis, chronic abdominal pain, diabetes, hepatic steatosis, and cognitive issues.
(833) 317-6278 
